Ricevi le ultime notizie sulle azioni Taysha Gene Therapies con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di TSHA

Ultime notizie per

Taysha Gene Therapies

Taysha Gene Therapies, Inc. - Common Stock

Taysha Gene Therapies Inc

Arbutus Biopharma Corporation - Common Stock

Arbutus Biopharma

AnaptysBio

BridgeBio Oncology Therapeutics, Inc. - Common Stock

BridgeBio Oncology

Biohaven

CureVac

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

Immatics

Inhibrx Biosciences

Kodiak Sciences

MiMedx Group

Nanobiotix

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics

Novavax

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals

Pharming Group N.V. - ADS, each representing 10 ordinary shares

Pharming

Palvella Therapeutics, Inc. - Common Stock

Palvella Therapeutics

Relay Therapeutics

Rezolute

Sana Biotechnology

ARS Pharmaceuticals

Tango Therapeutics

Upstream Bio

UroGen Pharma

Xencor

Zymeworks

Taysha Gene Therapies (TSHA) Previsione

Notizie

Utili

Quote.Nav.option-chain

Valutazioni degli analisti

Insider trading

Vendite allo scoperto

Rapporto azionario

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.

Comments

Taysha Gene Therapies Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO